Nyenhuis D L, Rao S M, Zajecka J M, Luchetta T, Bernardin L, Garron D C
Department of Psychology and Social Sciences, Rush-Presbyterian-St. Luke's Medical Center, Chicago, IL 60612, USA.
J Int Neuropsychol Soc. 1995 May;1(3):291-6. doi: 10.1017/s135561770000028x.
We administered the Multiscale Depression Inventory (MDI) and the Beck Depression Inventory (BDI) to 84 multiple sclerosis (MS) patients, 101 patients diagnosed with major depression and 87 nonmedical, nonpsychiatric controls. The MDI consists of three separate depression scales measuring mood, vegetative, and evaluative symptoms. We found that: (a) MS patients did not significantly differ from the controls in mood symptoms, (b) the depression prevalence rate in MS patients was significantly lower when measured by the mood scale (17.7%) than by the BDI (30.5%) or MDI total score (26.6%), and (c) MS patients showed significantly less mood disturbance than a non-MS comparison group matched on BDI measured depression severity. We suggest that the inclusion of nonmood symptoms in self-report depression scales may artificially raise both prevalence rates and severity ratings of MS related depression and that the most valid measure of depression in MS is mood disturbance.
我们对84名多发性硬化症（MS）患者、101名被诊断为重度抑郁症的患者以及87名非医学、非精神科对照者进行了多维度抑郁量表（MDI）和贝克抑郁量表（BDI）测试。MDI由三个独立的抑郁量表组成，分别测量情绪、植物神经和评估症状。我们发现：（a）MS患者在情绪症状方面与对照组无显著差异；（b）用情绪量表测量时，MS患者的抑郁患病率（17.7%）显著低于用BDI（30.5%）或MDI总分（26.6%）测量时的患病率；（c）与在BDI测量的抑郁严重程度上匹配的非MS对照组相比，MS患者的情绪障碍明显更少。我们认为，自我报告抑郁量表中纳入非情绪症状可能会人为提高MS相关抑郁的患病率和严重程度评级，而MS中最有效的抑郁测量指标是情绪障碍。
